ClinicalTrials.Veeva

Menu

Mucopolysaccharidosis Type II Natural History

Regenxbio logo

Regenxbio

Status

Completed

Conditions

Mucopolysaccharidosis II

Study type

Observational

Funder types

Industry

Identifiers

NCT03529786
RGX-121-002

Details and patient eligibility

About

Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is caused by a deficiency of iduronate-2-sulfatase (IDS) leading to an accumulation of glycosaminoglycans (GAGs) in tissues of MPS II patients, resulting in characteristic storage lesions and diverse disease sequelae, and in patients with the more severe form of the disease, irreversible neurocognitive decline and higher morbidity and mortality than in patients with the attenuated form of the disease.

There is currently limited information on the natural history of MPS II, especially with respect to neurocognitive decline in patients with the more severe form of the disease. This study is planned to be an observational medical records review study (data collected retrospectively and no investigational product treatment or procedures) in subjects with the severe form of MPS II. Collectively, the data may inform the design of future MPS II gene therapy treatment studies and may be utilized as historical comparative control data.

Enrollment

36 patients

Sex

Male

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  1. Documented diagnosis of MPS II confirmed by enzyme activity as measured in plasma, fibroblasts, or leukocytes

  2. The subject has at least one of the neurocognitive assessments listed below, which occurred prior to age 6 and in or after 2006 in their medical records.

    1. Bayley Scales of Infant and Toddler Development (BSID), any version
    2. Differential Ability Scale (DAS), any version
    3. Griffiths Mental Development Scale (GMDS), any version
    4. Kaufman Assessment Battery for Children (KABC), any version
    5. Kinder Infant Development Scale (KIDS)
    6. Kyoto Scale of Psychological Development (KSPD), any version
    7. Leiter International Performance Scale (LIPS), any version
    8. Mullen Scales of Early Learning (MSEL), any version
    9. Vineland Adaptive Behavior Scales (VABS), any version
    10. Wechsler Intelligence Scale for Children (WISC), any version
    11. Wechsler Preschool and Primary Scale of Intelligence (WPPSI), any version
  3. If the subject has undergone hematopoietic stem cell transplantation (HSCT), they must have at least one neurocognitive assessment prior to HSCT.

Trial design

36 participants in 1 patient group

Retrospective
Description:
An observational medical records review study (data collected retrospectively) in subjects with the severe form of MPS II.

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems